|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sopik V, Iqbal J, Rosen B and Narod SA:
Why have ovarian cancer mortality rates declined? Part II.
Case-fatality. Gynecol Oncol. 138:750–756. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abu Hassan SO, Nielsen DL, Tuxen MK,
Petersen PH and Sölétormos G: Performance of seven criteria to
assess CA125 increments among ovarian cancer patients monitored
during first-line chemotherapy and the post-therapy follow-up
period. Future Sci OA. 3:FSO2162017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Capriglione S, Luvero D, Plotti F,
Terranova C, Montera R, Scaletta G, Schirò T, Rossini G, Panici
Benedetti P and Angioli R: Ovarian cancer recurrence and early
detection: May HE4 play a key role in this open challenge? A
systematic review of literature. Med Oncol. 34:1642017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuan SJ, Qiao TK, Qiang JW, Cai SQ and Li
RK: The value of DCE-MRI in assessing histopathological and
molecular biological features in induced rat epithelial ovarian
carcinomas. J Ovarian Res. 10:652017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goff BA, Agnew K, Neradilek MB, Gray HJ,
Liao JB and Urban RR: Combining a symptom index, CA125 and HE4
(triple screen) to detect ovarian cancer in women with a pelvic
mass. Gynecol Oncol. 147:291–295. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Q, Zhang W, Li DR and Li L:
Identification of two potencial serum biomarkers for ovarian cancer
and clinical validation thereof. Zhonghua Yi Xue Za Zhi.
88:1012–1016. 2008.(In Chinese). PubMed/NCBI
|
|
8
|
Yang ZJ, Yang G, Jiang YM, Ran YL, Yang
ZH, Zhang W, Zhang JQ, Pan ZM and Li L: Screening and
sero-immunoscreening of ovarian epithelial cancer associative
antigens. Zhonghua Fu Chan Ke Za Zhi. 42:834–839. 2007.PubMed/NCBI
|
|
9
|
Kandukuri SR and Rao J: FIGO 2013 staging
system for ovarian cancer: What is new in comparison to the 1988
staging system? Curr Opin Obstet Gynecol. 27:48–52. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Y: Consistency test of the paired
fourfold table. J Mathe Med. 23:386–387. 2010.
|
|
11
|
Han XR, Wen X, Li YY, Fan SH, Zhang ZF, Li
H, Sun XF, Geng GQ, Sun S, Huang SQ, et al: Effect of different
anesthetic methods on cellular immune functioning and the prognosis
of patients with ovarian cancer undergoing oophorectomy. Biosci
Rep. 37:pii: BSR20170915. 2017. View Article : Google Scholar
|
|
12
|
Teng C and Zheng H: Low expression of
microRNA-1908 predicts a poor prognosis for patients with ovarian
cancer. Oncol Lett. 14:4277–4281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao J, Yang JC, Ramachandran V, Arumugam
T, Deng DF, Li ZS, Xu LM and Logsdon CD: TM4SF1 regulates
pancreatic cancer migration and invasion in vitro and in vivo. Cell
Physiol Biochem. 39:740–750. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang YK, Fan XG and Qiu F: TM4SF1
promotes proliferation, invasion, and metastasis in human liver
cancer cells. Int J Mol Sci. 17:pii: E661. 2016. View Article : Google Scholar
|
|
15
|
Sun Y, Xu Y, Xu J, Lu D and Wang J: Role
of TM4SF1 in regulating breast cancer cell migration and apoptosis
through PI3K/AKT/mTOR pathway. Int J Clin Exp Pathol. 8:9081–9088.
2015.PubMed/NCBI
|
|
16
|
Park YR, Lee ST, Kim SL, Liu YC, Lee MR,
Shin JH, Seo SY, Kim SH, Kim IH, Lee SO and Kim SW: MicroRNA-9
suppresses cell migration and invasion through downregulation of
TM4SF1 in colorectal cancer. Int J Oncol. 48:2135–2143. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu H, Yan Y, Gao C and Yang Z: Expression
and clinical significance of TM4SF1 protein in epithelial ovarian
cancer. Chin J Oncol Prev Treat. 6:20–24. 2014.(In Chinese).
|
|
18
|
Jackson RA, Wu JS and Chen ES: C1D family
proteins in coordinating RNA processing, chromosome condensation
and DNA damage response. Cell Div. 11:22016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li G, Liu J, Abu-Asab M, Masabumi S and
Maru Y: XPB induces C1D expression to counteract UV-induced
apoptosis. Mol Cancer Res. 8:885–895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raheja R and Gandhi R: FXR1: Linking
cellular quiescence, immune genes and cancer. Cell Cycle.
15:2695–2696. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Majumder M, House R, Palanisamy N, Qie S,
Day TA, Neskey D, Diehl JA and Palanisamy V: RNA-binding protein
FXR1 regulates p21 and TERC RNA to bypass p53-mediated cellular
senescence in OSCC. PLoS Genet. 12:e10063062016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qian J, Hassanein M, Hoeksema MD, Harris
BK, Zou Y, Chen H, Lu P, Eisenberg R, Wang J, Espinosa A, et al:
The RNA binding protein FXR1 is a new driver in the 3q26-29
amplicon and predicts poor prognosis in human cancers. Proc Natl
Acad Sci USA. 112:3469–3474. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jo YS, Kim SS, Kim MS, Yoo NJ and Lee SH:
Frameshift mutation of FXR1 encoding a RNA-binding protein in
gastric and colorectal cancers with microsatellite instability.
Pathol Oncol Res. 23:453–454. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bing-bing Z, Wei Z, Qi W, Zhi-jun Y and Li
L: The effect of TIZ gene overexpression on biological
characteristics of epithelial ovarian cancer cells. Tumor.
32:2012.
|
|
25
|
Zheng HY, Zheng HY, Zhou YT, Liu EL, Li J
and Zhang YM: Changes of TIZ expression in epithelial ovarian
cancer cells. Asian Pac J Trop Med. 8:157–161. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wani N, Nasser MW, Ahirwar DK, Zhao H,
Miao Z, Shilo K and Ganju RK: C-X-C motif chemokine 12/C-X-C
chemokine receptor type 7 signaling regulates breast cancer growth
and metastasis by modulating the tumor microenvironment. Breast
Cancer Res. 16:R542014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sahingur SE and Yeudall WA: Chemokine
function in periodontal disease and oral cavity cancer. Front
Immunol. 6:2142015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li HY, Cui XY, Wu W, Yu FY, Yao HR, Liu Q,
Song EW and Chen JQ: Pyk2 and Src mediate signaling to
CCL18-induced breast cancer metastasis. J Cell Biochem.
115:596–603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L,
Zhang W, Li D and Li L: CCL18 from tumor-cells promotes epithelial
ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog.
55:1688–1699. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schutyser E, Struyf S, Proost P,
Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte
I, Saccani A, Allavena P, et al: Identification of biologically
active chemokine isoforms from ascitic fluid and elevated levels of
CCL18/pulmonary and activation-regulated chemokine in ovarian
carcinoma. J Biol Chem. 277:24584–24593. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wei Z, Ying-Zhu Y, Li L, Zhong-Mian P,
Zhi-Jun Y and Qi W: Study on the localization and quantification of
CCL18 protein in epithelial cells of ovarian cancer. J Guangxi Med
Univ. 9–13. 2014.
|
|
32
|
Lin A, Salvador A and Carter JM:
Multiplexed microsphere suspension array-based immunoassays.
Methods Mol Biol. 1318:107–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
